Beam Therapeutics Inc. (BEAM) is having the kind of Monday that biotech investors dream about. Shares rocketed more than 23% after the company dropped a flurry of pipeline updates and strategic priorities that paint a surprisingly clear path forward through 2026 and beyond.

The FDA News That's Moving the Needle

Here's the headline grabber: Beam has reached alignment with the FDA on a potential accelerated approval pathway for BEAM-302, its treatment for alpha-1 antitrypsin deficiency (AATD). The approval pathway would use biomarker endpoints, which is a big deal for rare disease treatments where traditional endpoints can be challenging. The company is now planning to enroll roughly 50 additional patients at the optimal biologic dose as part of an expanded Phase 1/2 study.

But that's not all. Beam also announced plans to file a Biologics License Application for risto-cel as early as the end of 2026. That's the kind of concrete timeline that gives investors something tangible to work with.

On the financial front, Beam estimates it closed out 2025 with approximately $1.25 billion in cash, cash equivalents and marketable securities. That figure includes $255.1 million from Bristol-Myers Squibb Co (BMY)'s acquisition of Orbital Therapeutics. The company expects this war chest to carry it through 2029, covering both the anticipated launch of risto-cel and the pivotal development program for BEAM-302.

What the Charts Are Saying

The technical picture looks pretty robust. Beam is now trading 24.3% above its 20-day simple moving average and 40.7% above its 100-day SMA, showing genuine short-term momentum. The RSI sits at 52.32, squarely in neutral territory, meaning there's room to run without hitting overbought conditions. The MACD is below its signal line, which suggests some caution, but the overall trend remains constructive.

Traders should keep an eye on the $35.50 resistance level. A breakout above that could signal continuation of the current rally, while a failure to push through might lead to some consolidation.

Zooming out, Beam has gained nearly 33% over the past 12 months, demonstrating that this isn't just a one-day wonder but part of a longer upward trajectory.

BEAM Price Action: Beam Therapeutics shares were up 23.67% at $34.07 at the time of publication on Monday. The stock is trading near its 52-week high of $35.25.